Retinal GABAergic Alterations in Adults with Autism Spectrum Disorder.

Q et al. (2024) gave one dose of arbaclofen to adults with autism and to neurotypical adults. They used a painless eye test called an electroretinogram to watch how the retina reacted to light flashes.

The team wanted to see if the drug could shift a retinal signal linked to GABA, the brain's main calm-down chemical. They compared the two groups before and after the pill.

Before the drug, adults with autism had bigger retinal a-waves than controls. One dose of arbaclofen brought the wave size in the autism group down to typical levels.

The change lasted only hours, but it showed the retina can reveal living GABA differences in autism. No side effects were reported.

Higgins et al. (2021) seems to disagree. They found that parietal GABA in autistic kids starts low but catches up by age nine. The key difference is age: the kids' levels normalize, while the adults in Q et al. still show a retinal GABA mark. Tissue also differs—brain versus eye—so both findings can be true.

Brondino et al. (2016) reviewed human trials of GABA drugs in autism and saw little proof of benefit. Q et al. adds a new twist: instead of asking if the drug helps behavior, they show it can normalize a biological signal. This moves the field from "does it work?" to "can we see it working?"

Wang et al. (2025) and Li et al. (2024) also peer into the eye in autism. They find blood-vessel and layer changes in children, while Q et al. spot a drug-shiftable electrical change in adults. Together, the retina is shaping up as a cheap, fast window into autism biology across ages.

You now have a 15-minute, non-invasive test that can show if a GABA drug hits its target in real time. Use it to screen participants for future medication trials or to check individual drug response before long prescriptions. Pair retinal scans with behavior data to see if biological change tracks with clinical gains.